ALLERGY THERAPEUTICS ORD 0.1P overview

Allergy Therapeutics plc (“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two pivotal trials Portfolio focus ed on high value growth products to enhance future profitability Ground-breaking Phase I trial of peanut allergy vaccine on track to commence in 2022 following recent FDA clearance of IND application with data expected sooner than previously anticipated P ivotal Phase III...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate ’s Phase I PROTECT trial in H1 2022 Topline data from first-in-human trial expected in H1 2023 A nalysis of data from earlier ex-vivo biomarker study, VLP001 , demonstrate s beneficial mode of action of the vaccine candidate 26 January 20 2...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL Primary endpoint Combined Symptom Medication Score (CSMS) achieved with clinically relevant improvement across both active treatment groups compared to placebo Statistically significant r eduction in CSMS seen in both active treatment groups of 29.1 % and 36.8% compared to...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the Year ended 30 June 2021 Record p re-R&D operating profit ahead of market expectations reflecting continued sales growth Successful ex-vivo VLP Peanut biomarker study showing 24 - fold reduction in allergenicity and beneficial efficacy profile paving the way for first-in-human trial in 2022 Strong cash balance of £40.3m providing sufficient funds with a small amount of debt under...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Trading update O perating profit strong and expected to be well ahead of market expectations E xpenses for 2021 significantly lower than expectations due to C OVID -19 and good cost management . S ome phasing of R&D and commercial costs expected to be carr ied over into 2022 Strong cash position expected at year end S uccessful Immuno BON launch es in Germany and Austria supported by encouraging clinical data 2 4...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the year ended 30 June 2020 Record level of pre R&D operating profit supported by robust sales and operational efficiency Strong cash position with Grass MATA MPL Phase III programme and initial Phase I peanut trial fully funded Exclusive licencing agreement signed for further virus like particle(VLP) candidates 23 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) , Saiba AG (“Saiba”) and DeepVax GmbH (“DeepVax”) Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH Group to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findings Builds on positive ongoing progress in VLP-based peanut...

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard 20-Jul-2020 / 07:30 GMT/BST Hardman & Co Research: Record sales and a COVID-19 wildcard AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short-course subcutaneous allergy immunotherapy (SCIT) platform, which continues to make strong market share gains in a competitive environment. Several products using the PQ...